Chrysea obtains unique intellectual property portfolio on the production of polyamines which have a key role in the autophagy induction process and potentially on successful ageing in mammals

Published at

Chrysea Limited, was incorporated with the purpose to develop healthy-lifespan nutritional and supplementation interventions supported by rigorous clinical research, aimed at maintaining naturally occurring anti-ageing mechanisms such as autophagy.

The company’s main technology is based on world-class synthetic biology capabilities spun-out of Professor Jens Nielsen’s labs at both the Technical University of Denmark (DTU) and the University of Chalmers in Sweden. The technologies are based on over 30 years of metabolic engineering know-how on the yeast Sacharomyces cerevisae also known as baker’s yeast. Yeast metabolism can be successfully re-wired using synthetic biology methodologies to turn yeasts into powerful cell factories for the production of valuable and naturally occurring products used for human-health applications.

Chrysea has acquired the full rights over a broad portfolio of unique intellectual property claiming the production of a variety of important naturally occurring polyamines, polyamine derivatives and conjugates of high value in various healthcare fields, including but not limited to the field of nutritional supplementation.

Chrysea uses its synthetic biology technology platform to produce a key naturally occurring polyamine that has autophagy regulation properties called 1,8-Diamino-4-azaoctane, N-(3-Aminopropyl)-1,4-diaminobutane. The same natural product is present in human diets and more concentrated in foods like wheat, soya and old cheeses, but unfortunately still in very small quantities, which makes the extraction process difficult, expensive and amount-limited. Chrysea is the first to consistently produce autophagy inducing polyamines in baker’s yeast in high quantity and quality as well as purity in a consistent manner. The company will now enter into the product-development stage to develop clean-label pure products supported by consumer-relevant evidence of safety, tolerability and benefit, with an initial focus on functional supplements and nutraceuticals positioning for the wellness market.

About Chrysea

Chrysea is a company developing healthy-lifespan nutritional and supplementation interventions supported by rigorous clinical research, aimed at optimising natural occurring mechanisms of successful ageing such as autophagy. The vision of the company is to make a contribution to the shift of focus from “disease”, to managing “wellness” and/or “functionality”. Instead of diagnosing diseases at a point in time, trajectories across an individual and eventually a populations life course, are being addressed to delay the onset of certain age/related diseases. More specifically in situations where the process of autophagy plays anti-ageing potential benefits.

About Autophagy

Autophagy, meaning “self-devouring” in Greek, is a highly conserved and natural regulated mechanism of cells that declines as humans age. Autophagy removes unnecessary or dysfunctional components from an organism. It allows the orderly degradation and recycling of cellular debris which need to be “cleaned up” to allow for cells to function properly. Defects in autophagy as we age have been linked to various age-related human diseases, including neurodegeneration and cardiovascular ageing. The identification of the mechanisms of autophagy by Japanese researcher Yoshinori Ohsumi, eventually led him to the award of the 2016 Nobel Prize in Physiology or Medicine.

Go to the news index